Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels. It is not approved for use in any country,... It is not approved for use in any country, but is currently in clinical trials in the United States.
- Mechanism
- Curator reviewed
The mechanism of action of azimilide is to block both the slowly conducting (I(Ks)) and rapidly conducting (I(Kr)) rectifier potassium currents in cardiac cells. This differs from other class III agents that block I(Kr) exclusively or in combination with sodium, calcium, or transient outward (I(to)) potassium current channels. It also has blocking effects on sodium (I(Na)) and calcium currents (I(CaL)). Its effects on reentrant circuits in infarct border zones causing ventricular tachyarrhythmias are unknown.
- Primary indication
- Investigated for use/treatment in arrhythmia and atrial fibrillation.Curator reviewed
- Formula / weight
- C23H28ClN5O3 · 457.96 g/mol (avg)
- Also known as
- 1-((5-(P-CHLOROPHENYL)FURFURYLIDENE)AMINO)-3-(4-(4-METHYL-1-PIPERAZINYL)BUTYL)HYDANTOIN · 2,4-IMIDAZOLIDINEDIONE, 1-(((5-(4-CHLOROPHENYL)-2-FURANYL)METHYLENE)AMINO)-3-(4-(4-METHYL-1-PIPERAZINYL)BUTYL)-
Resolves to
MREBEPTUUMTTIA-PCLIKHOPSA-NSMILESCN1CCN(CCCCN2C(=O)CN(\N=C\C3=CC=C(O3)C3=CC=C(Cl)C=C3)C2=O)CC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Azimilide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account